KINAXO Expands Technology Platform and Secures Additional Venture Capital
Complete the form below to unlock access to ALL audio articles.
KINAXO Biotechnologies GmbH is expanding its technology platform to include mass spectrometry. This will allow KINAXO to better serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.
The in-house mass spectrometry facility is supported by scientific advisors Jesper Olsen and Juergen Cox, two experts from the department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Martinsried. KINAXO's technical equipment comprises an ultra-sensitive LTQ Orbitrap mass spectrometer from Thermo Fisher Scientific.
New lead investor Mountain Partners AG and co-investor KfW provided venture capital to fund KINAXO's technology expansion. Seeding investor High-Tech Gruenderfonds as well as KINAXO's shareholders Max Planck Society, BioM AG, Axel Ullrich and Hellmut Kirchner also participated in this financing round.
